USFDA completes inspection of Cadila Healthcare subsidiary

The US drug regulator inspected Cadila Healthcare's wholly-owned subsidiary Liva Pharma's injectables manufacturing unit in Vadodara, Gujarat. The inspection was carried on between August 20 to 28.

Liva is a 100 per cent subsidiary of Cadila Healthcare Limited. This was a product-specific pre-approval inspection, which concluded with 5 observations. Liva will revert to the USFDA in 15 days.

Zydus Cadila is a global pharma company that manufactures and markets a range of healthcare therapies. At 14:49 hours, Cadila Healthcare was quoting Rs. 389.20 per share, up by 1.83 per cent on Wednesday, when the benchmark BSE Sensex was at 38,863.24, down marginally by 33.39 or 0.09 per cent.